BCOP Self Study
NEW in 2020
- 20 hours of BCOP and ACPE credit
- 1 year of credit availability
- 1 combined post assessment (case study and post-test questions)
With releases scheduled for April and September, the 2020 Self-Study modules will feature cutting-edge discoveries from primary oncology literature published within the last two years. Emphasis will be on case-based application of the readings and content outlines. BCOP Self-Study Modules are on-demand and allow you to review and complete at your convenience for up to one year following the release of the education.
Each module will include access to articles, pre-assessment questions, patient cases and the BCOP post-test. You may choose to complete all or select individual modules, receiving BCOP credit for each completed module which achieves a passing score of 75% or above.
- Leading experts from a variety of specialties and settings
- Therapeutic developments translated into case-based reviews
- Application of information to practice-based scenarios
- Credit given per module – choose one or all
Release I (education released April 2020)
- Module 1 - Updates in the Treatment of Pancreatic Adenocarcinoma – Sarah Timaeus, PharmD BCOP (2.0 BCOP/ACPE)
- Module 2 - Anti-Coagulation – Whitney Lewis, RPh PharmD BCOP (2.5 BCOP/ACPE)
- Module 3 - Immune Checkpoint Inhibitors in HIV-Positive Patients with Advanced Cancer – Suwicha (Nan) Limvorasak PharmD BCOP (2.0 BCOP/ACPE)
- Module 4 - Updates in Non-Malignant Hematology: Focus on Hemophilia A and Thrombotic Thrombocytopenic Purpura (TTP) – Angela German, PharmD BCOP (2.0 BCOP/ACPE)
HOPA Member Price: $165
Non-Member Price: $215
Release II (education released September 2020)
- Module 5 - Hyperprogression with Immunotherapy – Kirollos Hanna, PharmD BCOP BCPS (1.5 BCOP/ACPE)
- Module 6 - CINV in Transplantation – Julianne Orr, PharmD BCOP (2.0 BCOP/ACPE)
- Module 7 - Early Antibiotic De-Escalation – Carissa Treptow, PharmD BCOP (2.0 BCOP/ACPE)
- Module 8 - NSCLC – Sarah Hayes, PharmD BCOP and Melvin Rivera, PharmD BCOP (3.0 BCOP/ACPE)
- Module 9 - Gastric and Esophageal Cancers – Matthew Arango, PharmD BCOP (3.0 BCOP/ACPE)
HOPA Member Price: $215
Non-Member Price: $280
2020 Self-Study Bundle – Purchase both modules as a bundle and save.
HOPA Member Price: $360
Non-Member Price: $480
2020 Self-Study is also a part of the 2020 BCOP Complete Program Bundle. Purchase the suite of all 2020 BCOP education, including BCOP Annual Conference and BCOP Updates Course, and save.
HOPA Member Price: $700
Non-Member Price: $1030
2019 Self-Study Release I is no longer available. Release II includes 3 modules and offers up to 7.5 BCOP/ACPE credits. It will be available through February 16, 2020
2019 BCOP Self-Study Modules – Release II
Module 5: Chronic Graft-versus-Host Disease - 2.5 hours
Description: Chronic graft-versus-host disease (cGVHD) is a major complication following allogeneic hematopoeitic stem cell transplantation which can significantly impact patients' quality of life. Systemic corticosteroids are considered first-line therapy but often associated with inadequate response and a host of side-effects. Evidence-based, consensus guidelines are lacking in terms of the best approach to treating patients with steroid-refractory cGVHD. This self-study module aims to provide information on new approaches to treating steroid-refractory cGVHD. This module will highlight three articles outlining the only FDA approved drug for cGVHD, ibrutinib, new data on ruxolitinib and a cost-efficacy comparison of agents currently used in the management of cGVHD. Upon completion, the audience should gain a better understanding of second-line treatment options for patients experiencing cGVHD including mechanisms of action, monitoring, counseling, and side-effect management utilizing these therapies.Learning Objectives
- Review the pathophysiology of cGVHD including how it relates to novel treatment options
- Summarize the data from clinical trials on the use of ibrutinib and ongoing trials with ruxolitinib in the treatment of cGVHD
- Describe the role of ibrutinib and ruxolitinib in the treatment of steroid-refractory cGVHD
- Explain the cost-effectiveness of various therapies used in the treatment of steroid-refractory cGVHD
Speaker: Robert S. Mancini, PharmD BCOP
Disclosure:Takeda Oncology – SP – H
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.5 contact hours (.25 CEUs) under the ACPE universal activity number 0465-0000-19-073-H04-P.
Activity Type: Application
Module 6: Adolescent and Young Adult (AYA) - 2.5 hours
Description: The adolescent and young adult (AYA) oncology self-study will focus on reproductive health in survivors as one of many late endocrine effects of cancer treatment. This self-study will review recent articles that characterize late endocrine effects in AYA cancer survivors and provide an in-depth review of the impact of cancer treatment on male and female reproductive health. This module will also explore the role of hormone replacement therapy in optimizing reproductive health outcomes in AYA cancer survivors.
- Predict the types of endocrine late effects of cancer and cancer treatment in AYA survivors
- Identify cancer-related factors that affect future reproductive health and fertility in male and female AYA survivors
- Interpret the role of hormone replacement therapy in optimizing the reproductive health of male and female AYA survivors
Speaker: Jocelyn Mohs, PharmD BCOP
Disclosure: No financial relationships exist with commercial interests.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.5 contact hours (.25 CEUs) under the ACPE universal activity number 0465-0000-19-075-H04-P.
Activity Type: Application
Module 7: Pharmacy Accreditation - 2.5 hours
Description:Expanded use of specialty pharmacy products has added to the complexity of the US Healthcare System. While not specific to treatment of cancer, specialty pharmaceuticals make up a growing number of oncology products, particularly oral oncolytics. With the growing utilization of specialty pharmacy products, interactions between specialty pharmacies, ambulatory care clinics, hospitals, and manufacturers are becoming more common. This self-study module will review relevant articles chronicling development and implementation of specialty pharmacy programs, as well as specific articles describing specialty pharmacy experiences in malignant hematology and oncology populations.
- Analyze initial steps needed to implement a specialty pharmacy.
- Explore best practices related to patient-centered specialty pharmacy practices
- Summarize key processes related to initiation, monitoring and follow-up of oncology specialty pharmaceuticals.
Speaker:Matthew Eckley, PharmD BCOP BCPS
Disclosures: Takeda Oncology – E – S, ST, EQ
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2.5 contact hours (.25 CEUs) under the ACPE universal activity number 0465-0000-19-074-H04-P.
Activity Type: Application
HOPA Member Price: $165
Non-Member Price: $225
2019 BCOP Self-Study – Release II is also a part of both the 2019 BCOP Program Bundle and BCOP Self-Study Online Module Bundle. If you've already purchased the 2019 BCOP Program Bundle or BCOP Self-Study Online Module Bundle, you can access your Self-Study Modules in My Education Library.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE test must be completed by February 16, 2020.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Test must be completed by February 16, 2020.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.